Suppressors of cytokine signalling-3 and -1 in human carcinogenesis

Frontiers in Bioscience - Scholar

Volumn 5 S, Issue 1, 2013, Pages 277-283

  Culig, Zoran ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Apoptosis; Cancer; Cytokine signaling; Cytokines; Review; Suppressor; Tumor suppressor

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE; CYCLINE; CYTOKINE; CYTOKINE RECEPTOR; FIBROBLAST GROWTH FACTOR 2; GELATINASE B; MITOGEN ACTIVATED PROTEIN KINASE; PROSTATE SPECIFIC ANTIGEN; PROTEIN INHIBITOR OF ACTIVATED STAT; PROTEIN KINASE B; STAT3 PROTEIN; STAT5 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING 3; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; SUPPRESSOR OF CYTOKINE SIGNALING;

APOPTOSIS; CANCER CELL; CANCER GROWTH; CARCINOGENESIS; CELL PROLIFERATION; CUTANEOUS T CELL LYMPHOMA; DOWN REGULATION; GLIOBLASTOMA; HUMAN; LIVER CARCINOGENESIS; LUNG CANCER; MELANOMA CELL; PERSONALIZED MEDICINE; PLEURA MESOTHELIOMA; PROMOTER REGION; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; THYROID TUMOR; ANIMAL; CELL TRANSFORMATION; METABOLISM; NEOPLASM;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; NEOPLASMS; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS;

EID: 84883703141     PISSN: 19450516     EISSN: 19450524     Source Type: Journal    
DOI: 10.2741/s372     Document Type: Review

References (54)

1. MF Neurath, S Finotto: IL-6 signaling in autoimmunity, chronic inflammation and inflammation-Associated cancer. Cytokine Growth Factor Rev 22, 83-89 (2011)
2. L Wallner, J Dai, J Escara-Wilke, J Zhang, Z Lao, Y Yu, M Trikha, JA Nemeth, ET Keller: Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice. Cancer Res 66, 3087-3095 (2006)
3. BA Croker, H Kiu, SE Nicholson: SOCS regulation of the JAK/STAT signalling pathway. Cell Dev Biol 19, 414-422 (2008)
4. A Yoshimura, T Naka, M Kubo: SOCS proteins cytokine signalling and immune regulation. Nat Rev Immunol 7, 454-465 (2007)
5. B He, L You, K Uematsu, M Matsangou, Z Xu, M He, F McCormick, D Jablons: Cloning and characterization of a functional promoter of the human SOCS-3 gene. Biochem Biophys Res Commun 301, 386-391 (2003)
6. D Massiocchi, A Gelain, S Villa, F Meneghetti, D Barlocco: Signal transducer and activator of transcription 3 (STAT3): a promising target for anticancer therapy. Future Med Chem 3, 567-597 (2011)
7. B He, L You, K Uematsu, K Zang, Z Xu, AY Lee, JF Costello, F McCormick, DM Jablons: SOCS-3 is frequnelty silenced by hypermethylation and suppresses cell growth in human lung cancer. Proc Natl Acad Sci USA 100, 14133-14138 (2003)
8. A Weber, UR Hegge, W Bardenheuer, I Tischoff, F Sommerer, A Markwarth, A Dietz, C Wittekind, A Tannapfel: SOCS-3 is frequently methylated in head and neck squamous cell carcinoma and its precursor lesions and causes growth inhibition. Oncogene 24, 6699-6708 (2005)
9. Y Niwa, H Kanda, Y Shikauchi, A Saiura, K Matsubara, T Kitagawa, J Yamamoto, T Kubo, H Yoshikawa:Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signaling in human hepatocellular carcinoma. Oncogene 24, 6406-6417 (2005)
10. H Ogata, T Kobayashi, T Chinen, H Takaki, T Sanada, Y Minoda, K Koga, G Takaesu, Y Maehara, M Iida, A Yoshimura: Deletion of the SOCS3 gene in liver parenchymal cells promotes hepatitits-induced hepatocarcinogenesis. Gastroenterology 131, 179-193 (2006)
11. H Isomoto, JL Mott, S Kobayashi, NW Werneuburg, SF Bronk, S Haan, GJ Gores: Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing. Gastroenterology 132, 384-396 (2007)
12. M Martini, R Pallini, G Luongo, T Cenci, C Lucantoni, LM Larocca: Prognostic relevance of SOCS3 hypermethylation in patients with glioblastoma multiforme. Int J Cancer 123, 2955-2960 (2008)
13. EC Brantley, LB Nabors, GY Gillespie, YH Choi, CA Palmer, K Harrison, K Roarty, EN Benveniste: Loss of protein inhibitors of activated STAT-3 expression in glioblastomamultiforme tumors: implications for STAT-3 activation and gene expression. Clin Cancer Res 14, 4694-4704 (2008)
14. Y Ogata, T Osaki, T Naka, K Iwahori, M Furukawa, I Nagatomo, T Kijima, T Kumagai, M Yoshida, I Tachibana, I Kawase:Overexpression of PIAS3 suppresses cell growth and restores the drug sensitivity of human lung cancer cells in association with PI3-K/Akt inactivation. Neoplasia 8, 817-825 (2006)
15. K Iwahori, S Serada, M Fujimoto, S Nomura, T Osaki, CM Lee, H Mizuguchi, H Takahashi, B Ripley, M Okumura, I Kawase, T Kishimoto, T Naka: Overexpression of SOCS3 exhibits preclinical antitumor activity against malignant pleural mesothelioma. Int J Cancer 129, 1005-1017 (2011)
16. MG Francipane, V Eterno, V Spina, M Bini, G Scerrino, G Buscerni, G Gulotta, M Todaro, F Dieli, R de Maria, G Stassi: Suppressor of cytokine signaling 3 sensitizes anaplastic thyroid cancer to standard chemotherapy. Cancer Res 69, 6141-6148 (2009)
17. C Brender, M Nielsen, K Kaltoft, G Mikkelsen, Q Zhang, M Wasik, N Billestrup, N Odum: STAT3-mediated constitutive expression of SOCS-3 in cutaneous T-cell lymphoma. Blood 97, 1056-1062 (2001)
18. G Vlotides, AS Sörensen, F Kopp, K Zitzmann, N Cengic, S Brand, R Zachoval, CJ Auernhammer: SOCS-1 and SOCS-3 inhibit IFN-Alpha-induced expression of the antiviral proteins 2,5-OAS and MxA. Biochem Biophys Res Commun 320, 1007-1014 (2004)
19. C Brender, P Lovato, VH Sommer, A Woetmann, AM Mathiesen, C Geisler, M Wasik, N Odum: Constitutive SOCS-3 expression protects T-cell lymphoma against growth inhibition by IFNalpha. Leukemia 19, 209-213 (2005)
20. J-H Cho-Vega, GZ Rassidakis, HM Amin, P Tsioli, K Spurgers, YK Remache, F Vega, AH Goy, F Giles, LJ Medeiros: Suppressor of cytokine signaling 3 expression in anaplastic large cell lymphoma. Leukemia 18, 1872-1878 (2004)
21. D Capello, C Deambrogi, D Rossi, T Lischetti, D Piranda, M Cerri, V Spina, S Rasi, G Gaidano, M Lunghi: Epigenetic inactivation of suppressors of cytokine signaling in Philadelphia-negative chronic myeloproliferative disorders. Br J Haematol 141, 504-511 (2008)
22. S Vilop, TB van Gemmeren, MH Lentjes, H van England, JG Herman, TH Brummendorf, E Jost, O Galin: Methylation-Associated dysregulation of the suppressor of cytokine signalin-3 in multiple myeloma. Epigenetics 6, 1047-1052 (2011)
23. RJ Rigby, JG Simmons, G Greenhalgh, WS Alexander, PK Lund: Suppressor of cytokine signaling 3 (SOCS3) limits damage-induced crypt hyperproliferation and inflammation-Associated tumorigenesis in the colon. Oncogene 26, 4833-4841 (2007)
24. I Bellezza, H Neuwirt, C Nemes, IT Cavarretta, M Puhr, H Steiner, A Minelli, G Bartsch, F Offner, A Hobisch, W Doppler, Z Culig: Suppressor of cytokine signaling-3 antagonizes cAMP effects on proliferation and apoptosis and is expressed in human prostate cancer. Am J Pathol 169, 2199-2208 (2006)
25. M Puhr, FR Santer, H Neuwirt, M Susani, JA Nemeth, A Hobisch, L Kenner, Z Culig: Down-regulation of suppressor of cytokine signaling-3 causes prostate cancer cell death through activation of the extrinsic and intrinsic apoptotic pathways. Cancer Res 69, 7375-7384 (2009)
26. F Pierconti, M Martini, F Pinto, T Cenci, S Capodimonti, A Calarco, PF Bassi, LM Larocca: Epigenetic silencing of SOCS3 identifies a subset of prostate cancer with an aggressive behavior. Prostate 71, 318-325 (2011)
27. H Neuwirt, M Puhr, IT Cavarretta, M Mitterberger, A Hobisch, Z Culig: Suppressor of cytokine signalling-3 is up-regulated by androgen in prostate cancer cell lines and inhibits androgen-mediated proliferation and secretion. Endocr Relat Cancer 14, 1007-1019 (2007)
28. J Matthews, T Almlöf, S Kietz, J Leers, JA Gustafsson: Estrogen receptor-Alpha regulates SOCS-3 expression in human breast cancer cells. Biochem Biophys Res Commun 335, 168-174 (2005)
29. GM Leong, S Moverare, J Brce, N Doyle, K Sjögren, K Dahlman-Wright, JA Gustafsson, KK Ho, C Ohlsson, KC Leung: Estrogen up-regulates hepatic expression of suppressors of cytokine signaling-2 and-3 in vivo and in vitro. Endocrinology 145, 5525-5531 (2004)
30. JL Barclay, ST Anderson, MJ Waters, JD Curlewis: Regulation of suppressor of cytokine signaling 3 (SOCS3) by growth hormone in pro-B cells. Mol Endocrinol 21, 2503-2515 (2007)
31. GJ Vanasse, RK Winn, S Rodov, A W Zieske, JT Li, JC Tupper, J Tang, EW Raines, MA Peters, KY Yeung, JM Harlan: Bcl-2 overexpression leads to increases in suppressor of cytokine signaling-3 expression in B cells and de novo follicular lymphoma. Mol Cancer Res 2, 620-631 (2004)
32. M Horndasch, Z Culig: SOCS-3 antagonizes proapoptotic effects of TRAIL and resveratrol in prostate cancer cells. Prostate 71, 1357-66 (2011)
33. M Puhr, FR Santer, H Neuwirt, G Marcias, A Hobisch, Z Culig: SOCS-3 antagonises the proliferative and migratory effects of fibroblast growth factor-2 in prostate cancer by inhibition of p44/p42 MAPK signalling. Endocr Relat Cancer 17, 525-538 (2010)
34. M Komyod, M Böhm, D Metze, PC Heinrich, I Behrmann: Constitutive suppressor of cytokine signaling 3 expression confers a growth advantage to a human melanoma cell line. Mol Cancer Res 5, 271-281 (2007)
35. K Hiwatashi, T Tamiya, E Hasagawa, T Fukaya, M Hashimoto, K Kakoi, I Kashiwagi, A Kimura, N Inoue, R Morita, H Yasukawa, A Yoshimura: Suppression of SOCS3 in macrophages prevents cancer metastasis by modifying macrophage phase and MCP/CCL8 induction. Cancer Lett 308, 172-180 (2011)
36. M Fojtova, V Boudny, A Kovarik, L Lauerova, L Adamkova, K Souckova, J Jarkovsky, J Kovarik: Development of IFN-gamma resistance is associated with attenuation of SOCS genes induction and constitutive expression of SOCS3 in melanoma cells. Br J Cancer 97, 231-237 (2007)
37. I Sakai, K Kakeuchi, H Yamauchi, H Narumi, S Fujita: Constitutive expression of SOCS3 confers resistance to IFN-Alpha in chronic myelogenous leukemia cells. Blood 100, 2926-2931 (2002)
38. H Neuwirt, M Puhr, FR Santer, M Susani, W Doppler, G Marcias, V Rauch, M Brugger, A Hobisch, L Kenner, Z Culig: Suppressor of cytokine signaling (SOCS)-1 is expressed in human prostate cancer and exerts growthinhibitory function through down-regulation of cyclins and cyclin-dependent kinases. Am J Pathol 174, 1921-1930 (2009)
39. J Strebovsky, P Walker, R Lange, AH Dalpke: Suppressor of cytokine signaling1 (SOCS1) limits NFkappa B signaling by decreasing p65 stability within the cell nucleus. FASEB J 25, 863-874 (2011)
40. FA Mallette, V Calabrese, S Ilangumaran, G Ferbeyre: SOCS1, a novel interactive partner of p53 controlling oncogene-induced senescence. Aging 2, 445-452 (2010)
41. H Xiong, W Du, YJ Zhang, J Hong, WY Su, JT Tang, YC Wang, R Lu, JY Fang: Trichostatin A, a histonedeacetylase inhibitor, suppresses JAK2/STAT3 signaling via inducing the promoter-Associated histoneacetylation of SOCS1 and SOCS3 in human colorectal cancer cells. Mol Carcinog 51, 174-184 (2012)
42. TV Bagnyukova, VP Tryndak, L Muskhelishvili, SA Ross, FA Beland, IP Pogribni: Epigenetic downregulation of the suppressor of cytokine signaling1 (Socs)1 gene is associated with the STAT3 activation and development of hepatocellular carcinoma induced by methyl-deficience in rats. Cell Cycle 7, 3202-3210 (2008)
43. Y Oshimo, K Kuraoka, H Nakayama, Y Kitadai, K Yoshida, K Chayama, W Yasul: Epigenetic inactivation of SOCS-1 by CpG island hypermethylation in human gastric carcinoma. Int J Cancer 112, 1003-1009 (2004)
44. N Fukushima, N Sato, F Sahin, GH Su, RH Hruban, M Goggins: Aberrant methylation of suppressor of cytokine signalling-1 (SOCS-1) gene in pancreatic ductalneoplasms. Br J Cancer 89, 338-343 (2003)
45. A Saudemont, A Hamrouni, P Marchetti, J Liu, N Jouy, D Hetuin, F Colucci, B Quesnel: Dormant tumor cells develop cross-resistantce to apoptosis induced by CTLs or imatinib mesylate via methylation of suppressor of cytokine signaling 1. Cancer Res 67, 4491-4498 (2007)
46. TL Lee, J Yeh, C van Waees, Z Chen: Epigenetic modification of SOCS-1 differentially regulates STAT3 activation in response to interleukin-6 receptor and epidermal growth factor receptor signaling through JAK and/or MEK in head and neck squamous cell carcinomas. Mol Cancer Ther 5, 8-19 (2006)
47. E Ko, SJ Kim, JW Joh, CK Park, J Park, DH Kim: CpG island hypermethylation of SOCS-1 gene is inversely associated with HBV infection in hepatocellular carcinoma. Cancer Lett 271, 240-250 (2008)
48. T Yoshida, H Ogata, M Kamio, A Joo, H Shiraishi, Y Tokunaga, M Sata, H Nagai, A Yoshimura: SOCS1 is a suppressor of liver fibrosis and hepatitis-induced carcinogenesis. J Exp Med 199, 1701-1707 (2004)
49. MA Weniger, I Melzner, CK Menz, S Wegener, AJ Bucur, K Dorsch, T Mattfeldt, TF Barth, P Möller: Mutations of the tumor suppressor gene SOCS-1 in classical Hodgin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation. Oncogene 25, 2679-84 (2006)
50. LO Flowers, PS Subramaniam, HM Johnson: A SOCS-1 peptide mimetic inhibits both constitutive and IL-6 induced activation of STAT3 in prostate cancer cells. Oncogene 24, 2114-2120 (2005)
51. FJ Huang, PS Steeg, JE Price, WT Chiu, PC Chou, K Xie, R Sawaya, S Huang: Molecular basis for the critical role of suppressor of cytokine signaling-1 in melanoma brain metastasis. Cancer Res 68, 9634-9642 (2008)
52. Z Li, D Metze, D Nashan, C Müller-Tidow, HL Serve, C Poremba, TA Luger, M Böhm: Expression of SOCS-1, suppressor of cytokine signalling-1, in melanoma. J Invest Dermatol 123, 737-745 (2004)
53. H Zhou, R Miki, M Eeva, FM Fike, D Seligson, L Yang, A Yoshimura, MA Teitell, CA Jamieson, NA Cacalano: Reciprocal regulation of SOCS 1 and SOCS 3 enhances resistances to ionizing radiation in glioblastomamultiforme. Clin Cancer Res 13, 2344-2353 (2007)
54. K Zitzmann, S Brand, EN de Toni, S Baehs, B Göke, J Meinecke, G Spöttl, HH Meyer, CJ Auernhammer: SOCS 1 silencing enhances antitumor activity of type I IFNs by regulating apoptosis in neuroendocrine tumor cells. Cancer Res 67, 5025-5032 (2007)